{"id":14170,"external_id":"plugin_asdk_app_6aea91e28adc8191aaf959530f596136","name":"mondotwin-researcher","display_name":"mondoTWIN Researcher","developer":"SHRARE Technology AG","category":"Education & Research","listing_language":"en","listing_language_details":{"method":"cld-0.13.0/listing-v1","reliable":true,"detected_at":"2026-11-18T06:09:56Z","input_sha256":"ed7bff6f16425d7fe849e912b7091bfc29704f6fe2921c0f6d2b2ca0efa415d6","source_fields":["release.description","release.interface.short_description","release.interface.long_description"]},"version":"0.7.4","skill_count":7,"first_seen_at":"2026-11-18T06:00:37.915Z","last_seen_at":"2026-11-18T06:00:37.915Z","last_changed_at":"2026-11-18T06:00:37.915Z","install_count":null,"search_matches":[],"research_summary":null,"research_reviewed_at":null,"metadata":{"canonical_app_id":"asdk_app_6aea91e28adc8191aaf959530f596136","connector_id":"asdk_app_6aea91e28adc8191aaf959530f596136","created_at":"2026-11-04T03:17:28.403742Z","discoverability":"LISTED","id":"plugin_asdk_app_6aea91e28adc8191aaf959530f596136","is_template":false,"is_template_instance":false,"name":"mondotwin-researcher","release":{"app_ids":["asdk_app_6aea91e28adc8191aaf959530f596136"],"app_manifest":{"apps":{"mondotwin":{"id":"asdk_app_6aea91e28adc8191aaf959530f596136","required":true}}},"app_templates":[],"description":"Seven clinical-research skills on mondoTWIN's trial-registry and regulatory-guidance database: benchmark similar trials, count and compare registered trials with read-only SQL, report which endpoints and comparators the trials of an indication used and how they fared, review a protocol section against ICH, draft eligibility criteria from comparable trials, choose endpoints and estimands, and look up ICH or FDA guidance with quoted passages. Includes the mondoTWIN connector (OAuth sign-in).","display_name":"mondoTWIN Researcher","id":"pluginrel_d567764524ec8191be8168551fda9583","interface":{"brand_color":"#E30613","capabilities":["Search registered clinical trials by condition, drug, sponsor, phase and status","Read one trial's record: endpoints, arms, sponsors, outcome, registry records","Count and compare trials with read-only SQL over the twin's tables","Endpoint and comparator precedent for an indication, by phase","Draft eligibility criteria from comparable trials","Quote ICH and FDA guidance with the guideline and section","Genetic targets of a disease from Open Targets"],"category":"Education & Research","composer_icon_dark_url":null,"composer_icon_url":"https://files.openai.com/content?id=file_00000000c0508230bf79d0b37dbf3d93","default_prompt":"Find completed phase 2 and 3 trials of colchicine after myocardial infarction: enrolment, primary endpoint, stop reason.","default_prompts":["Find completed phase 2 and 3 trials of colchicine after myocardial infarction: enrolment, primary endpoint, stop reason.","How many phase 3 trials in idiopathic pulmonary fibrosis stopped early, and why?","What does ICH E9(R1) say about the while-on-treatment strategy? Quote the passage."],"developer_name":"SHRARE Technology AG","logo_url":"https://files.openai.com/content?id=file_000000004c308230bc6c1cb485575012","logo_url_dark":null,"long_description":"Seven skills for clinical researchers who design trials: benchmark similar registered trials, count and compare trials across the registries (phases, enrolment, endpoints, stop reasons, sponsors), report which primary endpoints the trials of an indication used and how often each succeeded, by phase, and which comparators they used, review a protocol section against comparable trials and ICH guidance, draft eligibility criteria from comparable trials, choose endpoints and estimands, and quote ICH or FDA guidance. Every trial and passage is cited with its registry id or guideline section. After installing, connect the bundled mondoTWIN server once: the assistant opens the sign-in page, where you sign in or register a mondoTWIN researcher account (a new account waits for approval).","plugin_category_id":"education & research","privacy_policy_url":"https://www.mondotwin.com/privacy","screenshot_urls":[],"short_description":"Trial registries and guidance","terms_of_service_url":"https://www.mondotwin.com/terms","website_url":"https://www.mondotwin.com/researchers"},"keywords":["clinical-trials","protocol-design","eligibility-criteria","endpoints","comparators","estimands","ich-guidelines","fda-guidance","clinical-research"],"onboarding_skill_name":null,"requires_local_executor":false,"skills":[{"description":"Draft inclusion and exclusion criteria for a clinical trial from the criteria of comparable registered trials, and propose concomitant-medication exclusions from what those trials prohibit and from the investigational drug's likely interactions with background and commonly co-prescribed drugs. Use when the user asks to write, draft, compare, tighten or broaden eligibility criteria, inclusion/exclusion criteria, or prohibited and restricted medications for a study.","interface":{"brand_color":null,"default_prompt":null,"display_name":"eligibility-criteria","icon_large_url":null,"icon_small_url":null,"iconography":"hierarchy","short_description":"Draft inclusion and exclusion criteria for a clinical trial from the criteria of comparable registered trials, and propose concomitant-medication exclusions from what those trials prohibit and from the investigational drug's likely interactions with background and commonly co-prescribed drugs. Use when the user asks to write, draft, compare, tighten or broaden eligibility criteria, inclusion/exclusion criteria, or prohibited and restricted medications for a study."},"name":"eligibility-criteria","plugin_release_skill_id":"pluginrsk_6aeaa0dd2b5c81919b79a30bb104f2c9"},{"description":"Summarise which primary and key secondary endpoints comparable registered trials used and at which time points, and draft the estimand for a trial objective following ICH E9(R1) (treatment, population, variable, intercurrent events with their strategies, population-level summary). Use when the user is choosing or justifying a primary or secondary endpoint, asks what similar trials measured and when, or asks to define, check or write an estimand or an intercurrent-event strategy.","interface":{"brand_color":null,"default_prompt":null,"display_name":"endpoint-and-estimand","icon_large_url":null,"icon_small_url":null,"iconography":"chart","short_description":"Summarise which primary and key secondary endpoints comparable registered trials used and at which time points, and draft the estimand for a trial objective following ICH E9(R1) (treatment, population, variable, intercurrent events with their strategies, population-level summary). Use when the user is choosing or justifying a primary or secondary endpoint, asks what similar trials measured and when, or asks to define, check or write an estimand or an intercurrent-event strategy."},"name":"endpoint-and-estimand","plugin_release_skill_id":"pluginrsk_6aeaa0dc2c008191841ab1925cb48af1"},{"description":"Report which primary endpoints the registered trials of an indication used and how often each succeeded or failed, by phase, and which control arms and active comparators those trials used and how they fared, from mondoTWIN's twin. Use when the user asks which endpoints work or have succeeded for a disease, for endpoint precedent or success rates by endpoint, what primary endpoint a phase 3 should use, which comparator or control arm trials in the indication used, the standard-of-care comparator, placebo versus active comparator, or what trials in an indication have measured. Descriptive precedent, not a prediction.","interface":{"brand_color":null,"default_prompt":null,"display_name":"endpoint-comparator-precedent","icon_large_url":null,"icon_small_url":null,"iconography":"chart","short_description":"Report which primary endpoints the registered trials of an indication used and how often each succeeded or failed, by phase, and which control arms and active comparators those trials used and how they fared, from mondoTWIN's twin. Use when the user asks which endpoints work or have succeeded for a disease, for endpoint precedent or success rates by endpoint, what primary endpoint a phase 3 should use, which comparator or control arm trials in the indication used, the standard-of-care comparator, placebo versus active comparator, or what trials in an indication have measured. Descriptive precedent, not a prediction."},"name":"endpoint-comparator-precedent","plugin_release_skill_id":"pluginrsk_6aeaa0dd65c48191a182162cbb7a4cf6"},{"description":"Answer a question about ICH or FDA regulatory guidance with the exact passage quoted, the guideline id and the section. Use when the user asks what ICH (for example E6(R3), E8(R1), E9(R1), E10, M11, the Q series) or FDA guidance says about a topic, wants the source or exact wording of a regulatory expectation, or wants to check a statement against the guidance.","interface":{"brand_color":null,"default_prompt":null,"display_name":"guidance-lookup","icon_large_url":null,"icon_small_url":null,"iconography":"search","short_description":"Answer a question about ICH or FDA regulatory guidance with the exact passage quoted, the guideline id and the section. Use when the user asks what ICH (for example E6(R3), E8(R1), E9(R1), E10, M11, the Q series) or FDA guidance says about a topic, wants the source or exact wording of a regulatory expectation, or wants to check a statement against the guidance."},"name":"guidance-lookup","plugin_release_skill_id":"pluginrsk_6aeaa0dc26208191a17e05f8ba7567f1"},{"description":"Review a draft clinical trial protocol or synopsis section (objectives, endpoints, eligibility criteria, sample size rationale, schedule of activities) against comparable registered trials and ICH E6(R3), E8(R1), E9(R1) and M11, and return numbered, reasoned changes, each backed by trial registry ids or a quoted guideline passage and marked \"to validate\". Use when the user pastes or describes part of a protocol and asks for a review, critique, gap check, improvements, or consistency with ICH or with what similar trials did.","interface":{"brand_color":null,"default_prompt":null,"display_name":"protocol-section-review","icon_large_url":null,"icon_small_url":null,"iconography":"search","short_description":"Review a draft clinical trial protocol or synopsis section (objectives, endpoints, eligibility criteria, sample size rationale, schedule of activities) against comparable registered trials and ICH E6(R3), E8(R1), E9(R1) and M11, and return numbered, reasoned changes, each backed by trial registry ids or a quoted guideline passage and marked \"to validate\". Use when the user pastes or describes part of a protocol and asks for a review, critique, gap check, improvements, or consistency with ICH or with what similar trials did."},"name":"protocol-section-review","plugin_release_skill_id":"pluginrsk_6aeaa0dc28a881919fdb33b5dd4dd84d"},{"description":"Use when a question is to be answered from MondoTwin's twin of the pharma world through the twin MCP tools (twin_catalog, twin_find, twin_sql, twin_text, twin_record): a count, list, landscape or timeline of trials, drugs, products, approvals, indications, exclusivity, generics, companies, ownership, filings, papers, diseases or prevalence; reading a raw registry record, a label's text or an abstract; and before any analysis that cites the twin.","interface":{"brand_color":null,"default_prompt":null,"display_name":"query-database","icon_large_url":null,"icon_small_url":null,"iconography":"search","short_description":"Use when a question is to be answered from MondoTwin's twin of the pharma world through the twin MCP tools (twin_catalog, twin_find, twin_sql, twin_text, twin_record): a count, list, landscape or timeline of trials, drugs, products, approvals, indications, exclusivity, generics, companies, ownership, filings, papers, diseases or prevalence; reading a raw registry record, a label's text or an abstract; and before any analysis that cites the twin."},"name":"query-database","plugin_release_skill_id":"pluginrsk_6aeaa0dce9e88191b30c799629c1995d"},{"description":"Benchmark a planned or existing clinical trial against comparable registered trials (ClinicalTrials.gov, EU CTR/CTIS, ISRCTN, ANZCTR, UMIN) and return a table with registry id and link, phase, status, enrolment, primary endpoint and time frame, key eligibility criteria and stop reason. Use when the user asks for similar, comparable, competing or precedent trials, a trial landscape for a drug, indication or design, or \"what has been done before\" for a study they are planning.","interface":{"brand_color":null,"default_prompt":null,"display_name":"similar-trials-benchmark","icon_large_url":null,"icon_small_url":null,"iconography":"search","short_description":"Benchmark a planned or existing clinical trial against comparable registered trials (ClinicalTrials.gov, EU CTR/CTIS, ISRCTN, ANZCTR, UMIN) and return a table with registry id and link, phase, status, enrolment, primary endpoint and time frame, key eligibility criteria and stop reason. Use when the user asks for similar, comparable, competing or precedent trials, a trial landscape for a drug, indication or design, or \"what has been done before\" for a study they are planning."},"name":"similar-trials-benchmark","plugin_release_skill_id":"pluginrsk_6aeaa0dc1f108191978291f2d3e32080"}],"version":"0.7.4"},"scope":"GLOBAL","status":"ENABLED"},"research":null,"package_metadata":{"name":"mondotwin-researcher","author":{"url":"https://www.mondotwin.com","name":"SHRARE Technology AG / mondoTWIN"},"sources":[{"path":"plugin.json","sha256":"2bf5e8983119a18bc13f5bd12c6ee195254a1936738cff63de8b636b0d2b013a"},{"path":".claude-plugin/plugin.json","sha256":"d2817943de10d12af6722b9b8f9b8010f02322fc4de5f353e649b85cf3abcb5c"}],"version":"0.7.4","commerce":false,"homepage":"https://www.mondotwin.com/researchers","keywords":["clinical-trials","protocol-design","eligibility-criteria","endpoints","comparators","estimands","ich-guidelines","fda-guidance","clinical-research"],"repository":"https://github.com/mondotwin/mondotwin-researcher","artifact_id":283157,"observed_at":"2026-11-18T06:18:52Z","support_url":"https://github.com/mondotwin/mondotwin-researcher/issues","capabilities":["Search registered clinical trials by condition, drug, sponsor, phase and status","Read one trial's record: endpoints, arms, sponsors, outcome, registry records","Count and compare trials with read-only SQL over the twin's tables","Endpoint and comparator precedent for an indication, by phase","Draft eligibility criteria from comparable trials","Quote ICH and FDA guidance with the guideline and section","Genetic targets of a disease from Open Targets"],"field_sources":{"name":0,"author":0,"version":0,"commerce":0,"homepage":0,"keywords":0,"repository":0,"support_url":0,"capabilities":0,"release_notes":0,"review_case_counts":0},"release_notes":"0.7.4: all seven skills tell the user exactly where to connect the mondoTWIN server when its tools are missing (Claude: the Connect prompt or Customize > Connectors; ChatGPT: Plugins > mondoTWIN Researcher > Connect, then a new chat), instead of stopping. 0.7.3: the skills ask the user to connect the mondoTWIN server when its tools are missing, instead of stopping; the listing says the connector is connected once after installing. 0.7.2: listing category Education & Research and seven capability lines for the ChatGPT directory; no change to the skills. 0.7.1: query-database repaired: 0.7.0 shipped a damaged SKILL.md (method steps carrying rule text, the question-to-table router and the rules section missing); the skill is whole again, seven sections, rules R1 to R18, every recipe run on the served release. 0.7.0: query-database rewritten: the five twin tools with their measured limits, a seven-step method, a question-to-table router, 18 rules from the live catalog and 24 recipes each run on the served release, with the 58 tables one line each; nothing but the twin. 0.6.0: the connector moves to https://researchers.mondotwin.com/mcp, the researchers door: the same twelve read-only tools to every account; reconnect the mondoTWIN connector once. 0.5.0: endpoint-comparator-precedent, a new skill: which primary endpoints the registered trials of an indication used and how often each succeeded or failed, by phase, and which control arms and active comparators they used, from the twin's tables, with the n behind every rate. 0.4.0: query-database replaced query-clinical-studies: one read-only skill over the twin's tables (trials, drugs and products, approvals and indications, exclusivity, companies and filings, papers, diseases), its recipes run against the served release, the same text the platform's own analysts use. Seven skills for trial design research on mondoTWIN's twin of registered trials (ClinicalTrials.gov, EU CTR/CTIS, ISRCTN, ANZCTR, UMIN, ICTRP) and ICH and FDA guidance, with the mondoTWIN connector.","extraction_version":1,"review_case_counts":{"negative":3,"positive":5},"conflicts_or_errors":[]}}